Dose-adjusted EPOCH and rituximab (DA-EPOCH-R) inolder patients with high-risk aggressive diffuse large B-celllymphoma: A real-life multicenter study by the CroatianCooperative Group for Hematologic diseases (KroHem)

Mitrović, Zdravko; Dujmović, Dino; Jakšić, Ozren; Bašić-Kinda, Sandra; Gaćina, Petar; Periša, Vlatka; Prka, Željko; Dreta, Barbara; Galušić Davor; Holik, Hrvoje; Pejša, Vlatko; Aurer, Igor

doi:10.1111/ejh.13957

Pregled bibliografske jedinice broj: 1270694

Dose-adjusted EPOCH and rituximab (DA-EPOCH-R) in older patients with high-risk aggressive diffuse large B-cell lymphoma: A real-life multicenter study by the Croatian Cooperative Group for Hematologic diseases (KroHem)

(KroHem) Mitrović, Zdravko; Dujmović, Dino; Jakšić, Ozren; Bašić-Kinda, Sandra; Gaćina, Petar; Periša, Vlatka; Prka, Željko; Dreta, Barbara; Galušić Davor; Holik, Hrvoje et al.

Dose-adjusted EPOCH and rituximab (DA-EPOCH-R) in older patients with high-risk aggressive diffuse large B-cell lymphoma: A real-life multicenter study by the Croatian Cooperative Group for Hematologic diseases (KroHem) // European journal of haematology, 111 (2023), 13957, 7 doi:10.1111/ejh.13957 (međunarodna recenzija, članak, znanstveni)

CROSBI ID: 1270694 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Dose-adjusted EPOCH and rituximab (DA-EPOCH-R) in older patients with high-risk aggressive diffuse large B-cell lymphoma: A real-life multicenter study by the Croatian Cooperative Group for Hematologic diseases (KroHem)

Autori
Mitrović, Zdravko ; Dujmović, Dino ; Jakšić, Ozren ; Bašić-Kinda, Sandra ; Gaćina, Petar ; Periša, Vlatka ; Prka, Željko ; Dreta, Barbara ; Galušić Davor ; Holik, Hrvoje ; Pejša, Vlatko ; Aurer, Igor

Kolaboracija
KroHem

Izvornik
European journal of haematology (0902-4441) 111 (2023); 13957, 7

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
DA-EPOCH, diffuse large B-cell lymphoma, elderly, non-Hodgkin lymphoma, rituximab, treatment

Sažetak
Purpose: Dose-adjusted EPOCH and rituximab (DA- EPOCH-R) is a regimen used for the treatment of high-risk diffuse large B-cell lymphoma (DLBCL) designed to overcome resistance to standard R-CHOP by combining prolonged exposure of lymphoma cells to cytotoxic agents and dose-adjustment based on toxicity. Data on outcomes of older patients are scarce. Patients and Methods: We collected data on patients with newly diagnosed high-risk DLBCL older than 60 years treated with DA-EPOCH-R. High-risk patients were defined by the age-adjusted international prognostic index score 2 or 3. Results: A total of 120 patients were included. Median age was 69 years (range 60–82). Response rate was 74% ; with 59% complete responses. Dose of DA-EPOCH-R was escalated in 50 patients (42%). Three-year progression-free survival (PFS) and overall survival (OS) was 53% and 58%, respectively, with treatment-related mortality (TRM) of 13%. In univariate analysis, favorable prognostic factors were performance status (PS) (0–2 vs. 3– 4), age (<70 vs. ≥70 years), and center. In multivariate analysis, PS and center retained prognostic significance. Patients with PS 0–2 had 3-year PFS and OS of 58% and 64%, respectively, with TRM of 6%. Conclusion: DA-EPOCH-R is efficacious in sufficiently fit older high-risk DLBCL patients. Patients with poor PS have unacceptable toxicity and require less intensive therapy.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA

Ustanove:
Klinička bolnica "Merkur",
Stomatološki fakultet, Zagreb,
Medicinski fakultet, Zagreb,
Klinički bolnički centar Osijek,
KBC "Sestre Milosrdnice",
KBC Split,
Klinička bolnica "Dubrava",
Klinički bolnički centar Zagreb,
Medicinski fakultet, Split,
Medicinski fakultet, Osijek

Profili:

Davor Galušić (autor)